Global Cancer Biologics Market 2024–2033

Reports Description

As per the current market research conducted by the CMI arch Team, the global Cancer Biologics Market is expected to record a CAGR of 6.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 125.5 Billion. By 2033, the valuation is anticipated to reach USD 215.8 Billion.

The Cancer Biologics Market encompasses pharmaceutical products derived from living organisms or their components, designed to target specific molecules involved in cancer growth and progression. These biological therapies include monoclonal antibodies, cytokines, vaccines, and cell-based immunotherapies.

They offer targeted mechanisms of action, reduced toxicity compared to conventional treatments, and the potential for personalized treatment regimens. With advancements in biotechnology and oncology research, the Cancer Biologics Market continues to expand, offering innovative treatment options for various cancer types and driving improvements in patient outcomes and quality of life.

Cancer Biologics Market – Significant Growth Factors

The Cancer Biologics Market presents significant growth opportunities due to several factors:

• Increasing Cancer Incidence: The rising prevalence of cancer globally is a significant driver of the Cancer Biologics Market. As the burden of cancer grows, there is a growing demand for innovative and effective biological therapies to improve patient outcomes.

• Advancements in Biotechnology: Ongoing advancements in biotechnology have led to the development of novel biological therapies for cancer treatment. These advancements include the discovery of new therapeutic targets, the development of monoclonal antibodies, and the engineering of cell-based immunotherapies.

• Personalized Medicine Approaches: There is a growing emphasis on personalized medicine approaches in oncology, wherein biologic therapies are tailored to individual patient characteristics, genetic profiles, and disease subtypes. This personalized approach improves treatment efficacy, reduces adverse effects, and enhances patient satisfaction.

• Strategic Collaborations and Partnerships: Pharmaceutical companies are forming strategic collaborations and partnerships to accelerate the development and commercialization of biologic therapies for cancer. These collaborations involve licensing agreements, research collaborations, and co-development partnerships, leveraging complementary expertise and resources to drive innovation.

• Expansion into Emerging Markets: There is an opportunity for biopharmaceutical companies to expand their presence in emerging markets with high unmet medical needs. Emerging markets offer significant growth potential for Cancer Biologics, driven by increasing healthcare spending, improving access to healthcare, and rising awareness of advanced treatment options.

Cancer Biologics Market – Mergers and Acquisitions

The Cancer Biologics Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Biologics Market include:

• In 2022, Eli Lilly and Company received a complete response letter from the FDA regarding the Biologics License Application for sintilimab injection, a PD-1 inhibitor proposed for use alongside pemetrexed and platinum chemotherapy as a first-line treatment for individuals with nonsquamous non-small cell lung cancer (NSCLC).

• In 2023, Epigenomics AG introduced a multi-center clinical trial for a “Next-Generation” blood-based diagnostic screening test for colorectal cancer (CRC). This non-invasive option aims to boost screening rates and enhance diagnostic outcomes. The strategic launch significantly expanded the company’s customer base and generated substantial business revenue.

• In 2022, Gilead and Dragonfly have announced a research collaboration to advance natural killer cell engagers in oncology. Gilead obtained a worldwide license from Dragonfly for their 5T4 targeting immunotherapy program DF7001 as part of the agreement.

• In 2022, Gamida Cell’s allogeneic cell therapy Omisirge received FDA approval, promising to enhance access to stem cell transplants and improve patient outcomes. This milestone marks a significant advancement in the field of cell therapy and offers hope for patients in need of transplantation.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Biologics Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Cancer Biologics Market – Significant Threats

The Cancer Biologics Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• Patent Expirations: Patent expirations for key biologic therapies can lead to the entry of biosimilar competitors, resulting in market share erosion and pricing pressures for originator biologics.

• Regulatory Challenges: Stringent regulatory requirements for the approval of biologic therapies, including lengthy and costly clinical trials, pose challenges to market entry and product commercialization.

• High Development Costs: The high costs associated with research, development, and manufacturing of biologic therapies create barriers to entry for smaller companies and limit innovation within the market.

• Potential Safety Concerns: Biologic therapies may be associated with safety concerns such as immunogenicity, infusion reactions, and long-term adverse effects, which can impact patient confidence and acceptance of these treatments.

• Competition from Other Therapeutic Modalities: Competition from alternative treatment modalities such as small molecule drugs, chemotherapy, radiation therapy, and surgery may limit market share and adoption of biological therapies, particularly in certain cancer indications.

Category-Wise Insights

By Type of Biologic:

• Monoclonal Antibodies: Monoclonal antibodies are laboratory-produced molecules designed to target specific proteins in cancer cells, blocking their growth or signalling pathways. Trends include the development of antibody-drug conjugates for targeted delivery of cytotoxic agents and the emergence of bispecific antibodies for enhanced tumor targeting and immune activation.

• Vaccines: Cancer vaccines stimulate the immune system to recognize and destroy cancer cells. Trends include the development of therapeutic vaccines targeting tumor-specific antigens and the integration of personalized vaccine strategies, such as neoantigen vaccines, for individualized cancer treatment.

• Cytokines: Cytokines are signalling proteins that regulate immune responses against cancer. Trends include the development of engineered cytokines with improved pharmacokinetic properties and enhanced therapeutic efficacy, as well as the investigation of combination therapies involving cytokines and other biologics for synergistic anti-tumor effects.

• Gene Therapy: Gene therapy involves the delivery of genetic material to cancer cells to modulate their growth or induce cell death. Trends include the development of viral vectors for efficient gene delivery, the exploration of gene editing technologies like CRISPR/Cas9 for precise genetic modifications, and the investigation of oncolytic viruses as gene therapy vectors.

• Cell-Based Immunotherapies: Cell-based immunotherapies harness the power of immune cells to target and eliminate cancer cells. Trends include the development of chimeric antigen receptor (CAR) T-cell therapies for haematological malignancies, the optimization of manufacturing processes for scalable production of engineered immune cells, and the investigation of novel cell-based approaches like natural killer (NK) cell therapy.

• Others: Other biologic therapies in the Cancer Biologics Market may include oncolytic viruses, tumor-targeted antibodies, and immune checkpoint inhibitors. Trends in this segment involve the exploration of novel targets and mechanisms of action, the development of combination therapies to overcome resistance mechanisms, and the investigation of personalized treatment approaches based on patient-specific factors.

By Cancer Type

• Breast Cancer: Biologic therapies for breast cancer target specific receptors like HER2 or hormone receptors. Trends include the development of antibody-drug conjugates and immune checkpoint inhibitors, expanding treatment options and improving outcomes.

• Lung Cancer: Biologics for lung cancer often involve monoclonal antibodies targeting EGFR or PD-L1. Trends include personalized medicine approaches and combination therapies with chemotherapy or targeted agents, improving survival rates and quality of life.

• Colorectal Cancer: Biologic therapies for colorectal cancer target EGFR or VEGF pathways. Trends include the emergence of biosimilars and the development of immunotherapies, enhancing treatment efficacy and expanding patient access to innovative therapies.

• Prostate Cancer: Biologic therapies for prostate cancer target androgen receptors or prostate-specific antigens. Trends include the use of immunotherapies like sipuleucel-T and targeted therapies like PARP inhibitors, offering new treatment options for advanced prostate cancer.

• Leukaemia: Biologic therapies for leukaemia often involve monoclonal antibodies or CAR-T cell therapy targeting specific antigens on leukemic cells. Trends include the development of targeted therapies for different subtypes of leukaemia and the expansion of CAR-T cell therapy to other haematological malignancies.

• Lymphoma: Biologic therapies for lymphoma include monoclonal antibodies targeting CD20 or immune checkpoint inhibitors. Trends include the use of CAR-T cell therapy in relapsed/refractory lymphomas and the development of novel targeted agents, improving outcomes for patients with lymphoma.

• Others: Biologic therapies for other cancers may target specific pathways or antigens relevant to the tumor type. Trends include the exploration of novel targets and the development of combination therapies, addressing unmet needs in various cancer types.

By Route of Administration

• Intravenous: Intravenous administration involves delivering cancer biologics directly into the bloodstream. Trends include the preference for IV infusion in hospital settings due to precise dosing, rapid onset of action, and potential for combination therapies. Advancements in infusion pump technology enhance drug delivery accuracy and patient comfort.

• Subcutaneous: Subcutaneous administration delivers cancer biologics beneath the skin. Trends include a shift towards outpatient settings for convenience and reduced healthcare costs. Prefilled syringes and autoinjectors improve ease of administration, while the development of long-acting formulations enhances treatment adherence and patient satisfaction.

• Intramuscular: Intramuscular administration injects cancer biologics into muscle tissue. Trends include limited use in the Cancer Biologics Market due to challenges in drug absorption and patient discomfort. However, advancements in needle-free injection devices and sustained-release formulations may enhance the feasibility and acceptance of intramuscular administration for select biologics.

• Others: Other routes of administration for cancer biologics include oral, topical, and inhalation routes. Trends in these alternative routes focus on improving patient convenience, reducing healthcare burden, and exploring novel drug delivery technologies such as oral formulations, transdermal patches, and aerosolized formulations for targeted lung cancer therapy.

By Distribution Channel

• Hospital Pharmacies: Hospital pharmacies dispense cancer biology within healthcare facilities. Trends include increased collaboration with oncology departments to ensure timely access to biologic therapies, adoption of electronic prescribing systems for efficient medication management, and integration of specialty oncology pharmacists to provide personalized patient counseling.

• Retail Pharmacies: Retail pharmacies provide cancer biology for outpatient use. Trends include expanding specialty pharmacy services to manage complex oncology medications, offering patient education and support programs, and facilitating medication adherence through refill reminders and counseling services.

• Online Pharmacies: Online pharmacies offer cancer biology for purchase via internet platforms. Trends include the integration of telemedicine consultations for medication prescriptions, the implementation of secure digital platforms for medication ordering and fulfilment, and the provision of patient education resources for safe and effective medication use.

• Others: This category may include specialty oncology clinics, infusion centers, and specialty drug distribution companies. Trends may involve the development of integrated care models, partnerships with healthcare systems to streamline medication access, and the adoption of innovative drug delivery technologies to enhance patient convenience and adherence.

Report Scope

Cancer Biologics Market – Regional Analysis

The Cancer Biologics Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: In North America, a trend in the Cancer Biologics Market is the increasing adoption of novel immunotherapies and targeted therapies for cancer treatment. Additionally, there’s a growing focus on value-based care models and the integration of digital health technologies to improve patient outcomes and optimize healthcare delivery.

• Europe: In Europe, a significant trend in the Cancer Biologics Market is the emphasis on biosimilar development and adoption. Governments and healthcare systems are incentivizing the use of biosimilars to improve access to cost-effective cancer treatments while maintaining quality standards. Additionally, there’s a growing emphasis on personalized medicine approaches and collaborative research initiatives across European countries.

• Asia-Pacific: In the Asia-Pacific region, a key trend in the Cancer Biologics Market is the rapid expansion of healthcare infrastructure and the increasing prevalence of cancer. This region witnesses a growing demand for innovative biologic therapies, coupled with government initiatives to enhance cancer screening programs and access to advanced treatment options. Additionally, there’s a rising trend of partnerships between global pharmaceutical companies and local biotech firms to address regional healthcare needs.

• LAMEA (Latin America, Middle East, and Africa): In the LAMEA region, a notable trend in the Cancer Biologics Market is the increasing focus on the affordability and accessibility of cancer treatments. Governments and healthcare organizations are implementing policies to promote the use of generic and biosimilar biologic therapies, aiming to reduce treatment costs and improve patient access. Additionally, there’s a growing investment in oncology research and clinical trials to address the unique healthcare challenges in the region.

Competitive Landscape – Cancer Biologics Market

The Cancer Biologics Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

• Hoffmann-La Roche Ltd.
• Amgen Inc.
• Bristol Myers Squibb Company
• Merck & Co. Inc.
• Novartis International AG
• Pfizer Inc.
• AstraZeneca PLC
• Eli Lilly and Company
• Johnson & Johnson
• AbbVie Inc.
• Biogen Inc.
• Gilead Sciences Inc.
• Sanofi S.A.
• Celgene Corporation
• Takeda Pharmaceutical Company Limited
• Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the Cancer Biologics Market often adopt innovative approaches to differentiate themselves. Startups and emerging biopharmaceutical companies leverage advancements in drug discovery and development technologies to innovate new cancer biologics with improved efficacy and safety profiles.

Established key players such as Roche, Amgen, and Bristol Myers Squibb dominate the market due to their extensive experience, robust product portfolios, and global market presence. These key players lead in market share by continuously investing in research and development, conducting clinical trials, and securing regulatory approvals, ensuring their prominence in the market.

The Cancer Biologics Market is segmented as follows:

By Type of Biologic

• Monoclonal Antibodies
• Vaccines
• Cytokines
• Gene Therapy
• Cell-Based Immunotherapies
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma
• Others

By Route of Administration

• Intravenous
• Subcutaneous
• Intramuscular
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America